Business
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived
About this update from Purple Biotech Ltd.
[{"type":"image","alt":"Purple Biotech Ltd.","displaySize":"","headline":null,"caption":"Purple Biotech Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":250,"url":"https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uPUYH47gw3FQ7gEx5AqdsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1MA--/https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5","width":300,"height":250}},"lazy":false},{"type":"text","content":"Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment","length":220,"tagName":"p"},{"type":"text","content":"New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index","length":126,"tagName":"p"},{"type":"text","content":"Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived non-small cell lung cancer (NSCLC) biopsy, corresponding with IM1240 anti-tumor efficacy ","length":241,"tagName":"p"},{"type":"text","content":"REHOVOT, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer efficacy while minimizing toxicity, today announced new preclinical data supporting the clinical potential of IM1240, the Company’s lead CAPTN-3 tri-specific antibody. IM1240 is a conditionally activated, capped-CD3 × 5T4 × NKG2A tri-specific designed to direct tumor-selective T-cell activation while also leveraging NKG2A-mediated checkpoint inhibition to enhance anti-tumor activity.","length":645,"tagName":"p"},{"type":"text","content":"The new data, generated in the laboratory of Dr. Amir Horowitz of the Tisch Cancer Institute and the Lipschultz Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai, demonstrated potent anti-tumor activity for IM1240 across multiple treatment-resistant patient-derived tumor samples. All seven tested samples responded to IM1240 treatment, including samples fro...